Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06197269
Other study ID # LHMC/IEC/2019/41
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 15, 2022
Est. completion date April 14, 2024

Study information

Verified date December 2023
Source Lady Hardinge Medical College
Contact Sushma Nangia, DM (Neo)
Phone 9810838181
Email drsnangia@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Objective of the study is to compare the efficacy and safety of 'Short duration antibiotic' (72hrs) and 'Standard duration antibiotic'(5 - 7days) in preterm neonates ( >28weeks and >1000grams ) with culture negative early onset sepsis.


Description:

Enrolled participants will be randomly allocated to one of two study groups: 1) Short duration antibiotic' (72hrs), 2) Standard duration antibiotic'(5 - 7days) Short duration antibiotic group: Antibiotic therapy stopped at the time of randomization i.e. 72 hours after starting antibiotics Standard duration antibiotic group: antibiotics therapy continued for 5-7 days further after 72 hrs of starting antibiotics.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date April 14, 2024
Est. primary completion date February 14, 2024
Accepts healthy volunteers No
Gender All
Age group 28 Weeks to 36 Weeks
Eligibility Inclusion Criteria (All must be present) - All Preterm neonates (Gestational age >28weeks and >1000grams) - age less than 72hours of life - Started on antibiotic therapy based on presence of symptoms attributable to sepsis and /or positive sepsis screen but sterile blood culture - Symptoms resolved at time of randomization Exclusion Criteria: - Antibiotics started based on risk factors - Infants with major congenital anomalies or syndromes. - Presence of site specific infections including meningitis, pneumonia - Neonates suspected to have inborn errors of metabolism - Neonates with Severe birth asphyxia, (Apgar score at 5min <4 and cord Ph< 7.0,base excess <-16) - Neonates underwent major surgery in 1st week of life - Deemed by Doctor in charge to be sick enough to be continued on antibiotics

Study Design


Intervention

Other:
Short duration antibiotics
antibiotic therapy will be stopped at the time of randomization i.e. 72 hrs after starting treatment
Standard duration antibiotics
Antibiotics will be continued for 5-7 days more, 72 hrs after starting treatment.

Locations

Country Name City State
India Lady Hardinge Medical college New Delhi Delhi

Sponsors (1)

Lead Sponsor Collaborator
Lady Hardinge Medical College

Country where clinical trial is conducted

India, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of 'Treatment Failure' New onset appearance of clinical signs and symptoms requiring initiation of antibiotics 15 days of stopping antibiotics
Secondary Mortality Death due to any reason Till 1 month of life
Secondary Need for additional courses of antibiotic therapy Additional courses during the study time frame Till 1 month of life
Secondary Length of hospital stay Duration of hospital stay From date of birth until date of death or discharge whichever come assessed till 1 month of life
See also
  Status Clinical Trial Phase
Recruiting NCT06076200 - Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations
Completed NCT03694613 - Utility of Placental/Umbilical Cord Blood in Early Onset Neonatal Sepsis in Very Low Birth Weight Infants N/A
Recruiting NCT03819192 - Predicting EONS in PPROM Patients
Recruiting NCT03997266 - NICU Antibiotics and Outcomes Trial Phase 4
Recruiting NCT05329701 - Individualized Duration of Antibiotic Treatment in Early Onset Infection in Newborns. Phase 4
Not yet recruiting NCT06377397 - Selective Antibiotics When Symptoms Develop Versus Universal Antibiotics for Preterm Neonates Phase 3
Not yet recruiting NCT06100614 - Presepsin to Safely Reduce Antibiotics in Preterm Infants N/A
Not yet recruiting NCT05796115 - PROcalcitonin and Presepsin-guided Decision for Antibiotic Prophylaxis of EOS N/A